Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > S&P Biotech ETF is now up ~3% this year

<< Previous

Bullboard Posts

Next >>

Comment by rjc7on Dec 13, 2023 6:33pm

118 Views

Post# 35783349

RE:S&P Biotech ETF is now up ~3% this year

We are $0.03 away from the $0.41. Kinlytec has not been reflected in the share price and it's anyone's guess as to why. It will sooner than later become noticed. It's next milestone royalty payment as the project moves along will be the catalyst.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?